Methoxyflurane and Fentanyl in LBNP
Methoxyflurane and Fentanyl in the Lower Body Negative Pressure Model of Hypovolemia in Healthy Volunteers; a Randomized, Placebo-controlled Crossover Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
-
Oslo, Norway, 0586
- Oslo University Hospital
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Must be at least 18 years of age.
- Must be below 65 years of age.
- Signed informed consent and expected cooperation for the study and follow up must be obtained and documented according to ICH GCP, and national/local regulations.
Exclusion Criteria:
- Any medical condition limiting physical excertional capacity or requiring regular medication (allergy and oral contraceptives excepted)
- Pregnancy
- History of syncope (syncope of presumed vasovagal nature with known precipitating factor excepted)
- Any known cardiac arrhythmia
- History of renal disease
- History of liver disease
- Previous substance abuse
- Allery or known serious side-effects to opioids or methoxyflurane
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Active Comparator: Methoxyflurane
Inhalation methoxyflurane 99,9%, 3 ml, single dose.
Intravenous NaCl 9 mg/ml, XX ml, single dose.
|
LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia.
LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min.
LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
|
|
Active Comparator: Fentanyl
Intravenous fentanyl 50 microgr/ml, XX ml, single dose Inhalation NaCl 9 mg/ml, 3 ml, single dose.
|
LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia.
LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min.
LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
|
|
Placebo Comparator: Placebo
Intravenous NaCl 9 mg/ml, XX ml, single dose.
Inhalation NaCl 9 mg/ml, 3 ml, single dose.
|
LBNP is a model of experimental hypovolemia, whereby the lower body is exposed to negative pressure leading to sequestering of blood in the lower body and central hypovolemia.
LBNP will be induced stepwise with increments of 10 mmHg, each level lasting 1 min.
LBNP will be terminated at symptoms or signs of impending hemodynamic collapse.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cardiac output
Time Frame: Measured continuously during LBNP-exposure.
|
Cardiac output as measured by suprasternal Doppler and/ or non-invasive (volume clamp) pulse contour analysis.
|
Measured continuously during LBNP-exposure.
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Time to hemodynamic decompensation
Time Frame: 15 minutes
|
Time from start LBNP to symtomps or signs of hemodynamic decompensation (and termination of LBNP); defined by:
|
15 minutes
|
|
Mean arterial pressure
Time Frame: Measured continuously during LBNP-exposure.
|
Change in mean arterial blood pressure with increasing LBNP, as measured by the volume-clamp method.
|
Measured continuously during LBNP-exposure.
|
|
Stroke volume
Time Frame: Measured continuously during LBNP-exposure.
|
Change in cardiac stroke volume with increasing LBNP, as measured by suprasternal Doppler and/ or the volume-clamp method.
|
Measured continuously during LBNP-exposure.
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- lbnp_methoxy_fent_2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.